

21. (Amended) [The diagnostic agent for pancreatic exocrine function according to any one of claims 16 to 18] The method according to claim 16, wherein the ^{13}C - or ^{14}C -labeled oligosaccharide or polysaccharide is a cyclic oligosaccharide or polysaccharide.

22. (Amended) [A diagnostic agent for] A method for diagnosing pancreatic exocrine function, comprising administering to a subject a ^{13}C - or ^{14}C -labeled inclusion complex or a salt thereof having a cyclodextrin or a modified derivative thereof as a host molecule.

23. (Amended) [The diagnostic agent for pancreatic exocrine function according to any one of claims 16 to 22] The method according to claim 16, wherein the pancreatic exocrine function to be diagnosed is the ability of the pancreas to secrete α -amylase.

24. (Amended) [The diagnostic agent for pancreatic exocrine function according to any one of claims 16 to 22] The method according to claim 16, wherein the pancreatic exocrine function to be diagnosed is the ability of the pancreas to secrete α -amylase and at least one pancreatic exocrine enzyme other than α -amylase.

REMARKS

By this amendment, claims 25-42 have been cancelled. Accordingly, claims 1-24 are presented. No new matter has been added.

Applicant : Kohno et al.
Serial No. :
Filed : June 7, 2000
Page : 5

Attorney's Docket No.: 11127-002002


Applicant submits that all of the claims are now in condition for examination, which action is requested. Filed herewith is a check in payment of the excess claims fees required by the above amendments. Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

6/7/00

Chris T. Mizumoto
Reg. No. 42,899



Fish & Richardson P.C.
45 Rockefeller Plaza, Suite 2800
New York, NY 10111
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

30019137.doc

002030-67453560